ArcaScience Has Launched Flow AI Drug Assessment Software
The new system utilizes 24 specialized AI models to streamline regulatory-grade drug benefit-risk assessments.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do you trust AI software to accurately manage safety-critical data in pharmaceutical drug development?
ArcaScience has officially launched Flow, an AI-powered software platform designed to generate regulatory-grade drug benefit-risk reports. The system integrates 100 billion biomedical data points to help pharmaceutical companies evaluate drug safety profiles as new evidence emerges.
Why it matters
The platform addresses the need for faster, more accurate drug safety monitoring by automating the extraction and linking of adverse-reaction data from biomedical research. This technology supports pharmaceutical firms in maintaining rigorous safety standards throughout a drug’s lifecycle.
Flow integrates 24 specialized AI models with 100 billion biomedical data points to provide source-level traceability. In a benchmark test of 600 adalimumab abstracts, the system successfully recovered 104 out of 108 adverse-reaction concepts.
The players
ArcaScience
A biotechnology firm that develops artificial intelligence solutions for pharmaceutical regulatory submissions and drug safety.
Sanofi
A multinational pharmaceutical and healthcare company that is one of the partners currently collaborating with ArcaScience.
AstraZeneca
A global science-led biopharmaceutical company that maintains a partnership with ArcaScience for drug research.
GSK
A global biopharma company formerly known as GlaxoSmithKline that works with ArcaScience on drug development.
Takeda
A research-driven global biopharmaceutical company based in Japan that is among the partners utilizing ArcaScience technology.
The details
The software is designed to structure clinical evidence while maintaining full traceability to original sources. ArcaScience currently maintains partnerships with major pharmaceutical organizations including Sanofi, AstraZeneca, GSK, and Takeda.
Timeline
ArcaScience raised a $7 million seed round on September 23, 2025.
The Flow AI software was launched on September 23, 2026.
The Tech Race
This development represents a shift toward automating complex regulatory workflows that have historically relied on manual review. It follows a broader industry trend where private AI platforms are increasingly capable of matching or exceeding the speed of government-led surveillance projects like the FDA's Sentinel System.
For pharmaceutical teams, this software reduces the manual labor required to compile regulatory submissions by providing automated traceability to clinical sources. While the technology operates in the background, it aims to accelerate the availability of safe medications for patients.
The takeaway
The successful benchmarking of Flow against existing models highlights a turning point for AI in highly regulated clinical environments. As pharmaceutical companies integrate these tools, the speed of drug benefit-risk assessments is expected to increase without sacrificing regulatory rigor.
Further reading
Learn more about the latest innovations in Biotech to understand how artificial intelligence is transforming drug discovery and safety regulations.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust AI software to accurately manage safety-critical data in pharmaceutical drug development?
